NeuroVasx completes $8.5M financing

TriMed Staff | | Health Imaging | Screening
NeuroVasx, a catheter and implant technologies company to treat acute stroke, aneurysms and other cerebrovascular disorders, has completed a private placement of common stock in the amount of $8.5 million with Miller Johnson Steichen Kinnard of Minneapolis, Minn., and the Stephens Group of Little Rock, Ark.

Specific terms of the financing were not disclosed.

The Maple Grove, Minn.-based company also announced completion of follow-up on 20 patients treated with the cPAX Aneurysm Treatment System in a clinical study which was completed in May. The company is scheduled to announce the study results at the 2008 International Stroke Conference held in New Orleans, La. in February.

TriMed Staff

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.